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Abstract  
On-going new technology development in Continuous Manufacturing (CM) has enabled 
potential for significant step changes within the Pharmaceutical sector e.g. shifting from 
‘batch’ to ‘continuous’ processing has implications for (a) product variety, consistency 
and functionality (b) energy and resource efficiency (c) inventory and customization 
options and (d) overall industry structure. However, current adoption rates of CM remain 
in the range of 5%. This research looks to explore and address the operations and supply 
chain management challenges associated with CM, specifically through learning from 
other industrial systems.  
Research question(s): Emerging research questions include (a) what are the architectural 
differences between current (batch) and future (continuous) manufacturing operations 
and (b) associated implications for up-stream and down-stream supply chain 
configurations, structures, processes and systems.  
Methods: An Industrial landscape mapping methodology was developed (integrating 
value chain analysis with supply network configuration mapping) that is applicable to a 
broader industrial systems context. The pharmaceutical sector was mapped to provide the 
basis for (a) exploring alternative product-process supply network options and value 
chain implications of a shift to CM and (b) cross-sector analysis involving six previous 
case studies (i.e. six industrial systems that have exhibited different types of disruptive 
innovation).  
Key findings: This research provides a basis for understanding (a) current and future 
supply network configurations (b) critical interconnections between industry actors and 
(c) the overall industry structure. Preliminary cross-case analysis suggests several generic 
aspects to supply networks, including the blurring of industry boundaries, and the critical 
requirement to manage uncertainty in selective elements of the value chain. 
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Introduction 
 
On-going new technology development in the area of ‘Continuous Manufacturing’ (CM) 
has enabled potential for significant step changes within the Pharmaceutical sector e.g. 
shifting from traditional ‘batch’ to ‘continuous’ processing has implications for (a) 
product variety, consistency and functionality (b) energy and resource efficiency (c) 
inventory and customization options and (d) overall industry structure. While other 
industries, such as oil, gas, petrochemicals, polymers, and food currently operate in CM 
mode; extensive use of CM is still relatively new to the pharmaceutical industry where 
the current adoption rate of continuous processing is approximately 5 %. Despite the fact 
that 50% of reactions in pharma could benefit from a continuous process based on e.g. 
micro-reactor technology, the industry still dominated by batch processes and it is 
estimated that rejected batches, rework and investigations can equate to as much as 25% 
of pharmaceutical company revenues (Alinaghian et al. 2012, Arnum and Whitworth, 
2011). 
Continuous manufacturing is gaining ever-increasing attention within the 
pharmaceutical industry because of the expanding profitability gap experienced by most 
pharmaceutical companies (Gerogiorgis and Barton, 2009). Today, it is becoming more 
difficult for pharmaceutical companies to meet profit expectation, due to increasing 
research and development (R&D) operating costs and competition from generic 
manufacturers. A review of the fine and commodity chemical industries has demonstrated 
that continuous manufacturing could offer both operating expenditure (OpEx) and capital 
expenditure (CapEx) savings for the pharmaceutical industry. Furthermore, labor for 
transporting material between batch units, quality assurance/quality control (QA/QC), 
and in process inventory can all be significantly reduced in continuous manufacturing. 
According to the Trout research group, the increasing interest in continuous 
manufacturing can be attributed to a combination of three factors of the beginning of 
more flexible regulatory approaches, increasing cost pressure and increasing quality and 
controls specifications of pharmaceuticals (Schaber et al. 2011). 
 Hence, the pharmaceutical industry and the regulatory bodies are now actively 
encouraging the development and implementation of innovative pharmaceutical 
manufacturing systems e.g. a recent study into the future of High Value Manufacturing 
(HVM) in the UK, commissioned by the Technology Strategy Board, was published in 
February 2012 (TSB 2012). One of the HVM study recommendations was that particular 
manufacturing sectors should be explored in greater depth and this report presents the 
findings from studies of the pharmaceutical and biopharmaceutical sectors. Workshops 
were held for each sector attended by representatives from industry, government bodies 
and the research community.  The aims were to: 
 
• identify the needs and capability gaps to achieving innovation in manufacturing in 
each sector through to 2025 
• determine priority actions to meet these needs and build capability to enable 
innovation in manufacturing in each sector over this time scale 
• better define the HVM landscape with additional data from the Life Sciences 
sector. 
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Strategic road mapping techniques (see figure 1) were used to help participants 
explore the pharmaceutical sector’s key trends and drivers; the novel products, processes 
and services which could be developed in the future; any technologies and capabilities 
required to support these opportunities; and the enabling factors that would help the 
sector respond successfully. The list of potential new products, processes and services 
was prioritized to identify key areas where it was thought the most valuable opportunities 
for innovation exist. A ‘case for action’ was developed to justify further work in each 
area, outlining the potential benefits, critical gaps and steps required (TSB 2012). 
 
 
 
Figure 1. Opportunities for the Pharmaceutical sector in terms of integrated, 
outcome-based based supply chains - one of seven priority topics (TSB, 2012) 
 
 
Research Approach 
 
This specific research paper looks to initially explore research questions include (a) what 
are the architectural differences between current (batch) and future (continuous) 
manufacturing operations and (b) associated implications for up-stream and down-stream 
supply chain configurations, structures, processes and systems through e.g. 
 
• Exploration of the barriers and enablers for CM adoption within the 
pharmaceutical industry (Harrington et al, 2013) 
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• An Industrial landscape mapping methodology previously developed (Srai et al, 
2013) integrating value chain analysis with supply network configuration 
mapping) was used to map the pharmaceutical sector to provide the basis for 
exploring alternative product-process supply network options and value chain 
implications of a shift to CM.  
•   Cross-sector analysis involving six previous case studies (i.e. six industrial 
systems that have exhibited different types of disruptive innovation) e.g. 
• Defence Aerospace  (Service) 
• Maritime 
• Built-Environment 
• Industrial Biotechnology  (IB) 
• Photovoltaic  (PV) 
• Last Mile (LM) Logistics 
 
 
Industrial Landscape Mapping 
 
The industrial system mapping approach builds on techniques developed in mapping SN 
configurations (Srai and Gregory, 2008), across the manufacturing value chain (Srai and 
Shi, 2008). In these studies, the supply network configuration has been defined as “that 
particular arrangement or permutation, of the supply network’s key elements including, 
the “network structure” of the various operations within the supply network and their 
integrating mechanisms, the flow of materials and information between and within key 
“unit operations” the “role, inter-relationships, and governance” between key network 
partners, and the “value structure” of the product or service delivered”. Within this 
definition the four elements, which constitute the foundation of the configuration 
mapping approach, are: 
• Supply network structure; network tier structure and shape, composition, 
ownership, levels of vertical and horizontal integration, location, co-ordination, 
manufacturing processes, optimum sequence, complexity, flexibility, etc.  
• Material and Information Flow; both intra- and inter-key unit operations; value 
and non- value adding activities, process steps, optimum sequence, levels of 
flexibility, network dynamics (e.g. replenishment modes), infrastructure, and 
enabling IT systems 
• Relationships and Governance; the role, inter-relationships, and governance 
between key network partners; the nature of these interactions or transactions, 
number, complexity, partner roles, governance and trust  
• Product/Service value-structure; product composition and structure (including 
components, sub-assembly, platforms, modularity), product replenishment mode 
(e.g. is the product make- to-stock, make-to-order, configure-to-order), SKUs, 
products as spares, and through-life support and services 
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Extension to the industrial system level was a key requirement for effective industrial 
system and cross-case analysis. Hence, these mapping approaches were developed further 
in order to capture industry system level actors (institutional, industrial support as well as 
product supply chain actors) and explore linkages between them (Srai et al, 2013) e.g.  
• Identification of sector institutional players and secondary stakeholders e.g. 
research, industry development, specialist firms etc 
• Development of a Value Chain Process Map e.g. production processes and unit 
operations etc 
• Identification of the industry actors e.g. supply chain actors, organisational 
types, linkages between organisations, material, potential information and value 
flows etc  
• Technology process and product types e.g. Identification of substrates, process 
technologies etc 
 
 
 
Cross-sector analysis 
 
The integration of the methods outlined above, resulted in an industrial system-level 
mapping framework, which served as a consistent method of analysis to enable cross-
sector comparison. 
The industrial systems mapping framework was then used to inform e.g. 
• Capture of industry structure at a broad industrial systems level  
• Capture of alternative supply network configurations within the industrial system 
 
Industrial system context and structure mapping, involved focal firm case-­‐‑study 
investigations with actors from each of the main product categories, with focal-firm case-
selection based upon their central role in the value chain.  Respondents from focal firms 
informed the identification of various actors (Institutional, Industrial and SN) and to 
generate an understanding of key enablers of high value and emergence of each industrial 
system studied.  
Tables 1-5 summarise the key points for five of the industrial systems e.g. aerospace 
service, maritime, built environment, industrial biotechnology and last mile logistics.  
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Table 1. Observations from Industrial Landscape Mapping - Aerospace (Service) 
 
Trends & Drivers Emergence 
 
• Industrial Integration and leadership to deliver 
outcome-based contract management 
• Unique customized services  
• Contracting and sub-contracting mechanisms 
and protocols (formal/informal ConOps) e.g. 
engines, manpower, systems support, spare 
parts  
• Integrating Design and Build know how with 
Maintenance and Repairs  
• The ability to configure and reconfigure 
resources to provide capability to achieve 
desired effects  
• At an operational level, to achieve effective 
network integration across partners 
• Home market critical for historical sector 
evolution 
• Adaptability (Network design and operation) 
vital to meet adjacent and new markets 
(products and regions) 
 
 
 
 
• New Outcome based Service Models involving 
multiple partners  
• Emerging markets requiring more dispersed 
network capability 
• Through-life contracting models that are 
increasingly industrially dominated; industry 
penetrating into all elements of service delivery 
• Failure mode analysis driven by through-life 
costs as well as functional integrity 
• Unmanned aircraft demanding real-time 
information systems, remote trace and control 
• Blurring of sector boundaries: defence, 
Intelligence and information driven security 
systems (defensive and offensive) 
 
 
 
Table 2. Observations from Industrial Landscape Mapping - Maritime Sector 
 
Trends & Drivers Emergence 
 
• Design and Equipment Manufacturers enjoy 
high margin; assembly/shipyards do not 
• Highly customized niche products 
• High barrier to entry 
• In-house production provides capability to 
execute on novel designs 
• Direct customer interaction enabled through 
‘own production’; end-client conversation 
currently with ship-yards 
• No desire to compete in high volume 
commodity markets 
• Home market critical for cluster scale and 
consequent capability development 
• Adaptability (Network design and operation) 
vital to meet adjacent and new markets 
(products and regions) 
 
 
 
 
 
• Designers talking direct to end clients 
• Industry structure moving from many national 
players to International networks requiring 
firms with global scale  
• Blurring of sector boundaries: maritime, off-
shore wind, energy 
• Radical reconfiguration paths to meet new 
market sectors, new regions 
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Table 3. Observations from Industrial Landscape Mapping - Built Environment Sector 
 
Trends & Drivers Emergence 
 
 
 
• Rapid commercialization of new energy 
efficient technologies 
• Retro-fit installation capability 
• Urban environment requires tailored delivery 
models e.g. consolidation centres, local 
government support, community engagement  
• New concepts of value including carbon credits 
etc. 
 
 
• Regulation driving new business models 
• Regulatory uncertainty and ability to deliver, a 
barrier to industry growth 
• New ecosystem lacks natural leaders and 
champions 
• Demand requires step change in industry scale 
but no obvious migration paths 
• Fragmented network structure frustrates rapid 
evolution 
• Blurring of boundaries: construction, 
environment, energy; interface between 
government, industry and academia. 
 
 
 
 
Table 4. Observations from Industrial Landscape Mapping - Industrial Biotechnology 
 
Trends & Drivers Emergence 
 
• Platform technology serves multiple end-user 
markets 
• Upstream R&D, process technology and 
substrate developers introducing innovation 
• Downstream biochemical and industrial users 
of global scale – opportunities and barriers 
(sunk costs) 
• Feedstock growth and degradation determines 
upstream location, with complex intermediate 
biochemical processing and storing options  
• Relatively benign operating conditions, low 
CAPEX, lower minimum economies of scale, 
higher volume flexibility 
• Higher R&D costs and more complex process 
control 
• Close partnership between universities, 
demonstrator facilities, VCs and new players 
 
 
 
 
 
• Great uncertainty on adoption rates of new 
technology 
• Upstream players are small, recently formed 
and financially constrained with high attrition 
rates 
• Lack of connectedness and visibility between 
upstream emerging firms and downstream 
established actors; pairings between SMEs and 
MNCs emerging 
• Regulation can drive/hinder development  
• End-user market proliferation likely 
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Table 5. Observations from Industrial Landscape Mapping - Last Mile Logistics 
 
Trends & Drivers Emergence 
 
• Value generated by waste reduction and 
demand creation through new routes to market 
(more flexible, dependable, resource efficient) 
• Providing consumer choice; options on delivery 
mechanism, time, location and format 
• Mass and late customization enabled through 
customer-friendly information exchanges e.g. 
Apps, portals etc. 
• E-commerce and IT enabled elasticity of 
demand 
• Eliminating waste through consolidation 
(minimising missed deliveries, JIS, efficient 
forward/reverse logistics) 
• Consolidation centre enables value to be added 
at the local level (engaging new actors) whilst 
providing simplicity for remote suppliers and 
potential multi-modal connections. 
 
 
 
• New ‘route to customer’ models emerging 
o B2C e.g. Packages 
o B2B e.g. Construction, Retail 
logistics 
• Interface between regulators, local government, 
industry and end-users, and academia  
• Network Integration between governance 
bodies, industrial actors and end-users 
• Real-time information networks are key 
enablers 
• Blurring of industry boundaries: multi-modal 
solutions, IT and transport, product and service, 
retail/industry and logistics. 
 
 
In the context of this research, outputs from previous work (Alinaghian et al. 2012) 
suggests that many of the critical issues are not simply about a ‘batch to continuous shift’ 
but more about the alternative product-process supply network options and value chain 
implications of e.g. 
• Product variety, consistency and functionality 
• Energy and resource efficiency (e.g. capital investment, solvent use, number of 
process steps)  
• Inventory, minimum ‘lot’ size, customisation options etc. 
 
Table 6 presents the key trends, drivers and emerging factors for the pharmaceutical 
sector. Based on initial interviews with respondents, the following key questions were 
also identified e.g. 
• Pharma supply chain genuinely customer/consumer/patient driven? Intent? Know-
how?   
• Are business needs compelling for new supply chain models (vision, tangible)?  
• What products, diseases areas, therapy areas, patient populations should be 
targeted? 
• Industrial and technical feedback often contradicting; clarity on problem?  
• Consider radical change – incorporate potential supply chain disruptive influences 
• Realistic timeframes, investments/resources, delivery models, risks 
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Table 6. Preliminary Observations from Industrial Landscape Mapping – Pharmaceutical 
Sector 
 
Trends & Drivers Emergence 
 
• Smaller lot size, Personalization, Convergence 
with Diagnostics and Stratified Medicine 
• Cost of development 
• Complexity of supply chain, Changing 
Manufacturing locations 
• Collaboration, partnership and open innovation 
• Responsive regulation, Quality by design 
• Complex therapies and formulations 
• Price and cost pressures 
Key novel products, services and processes 
emerging: 
 
• Flexible, Distributed Factories 
• Integrated Design and Manufacture 
• Diagnostics and Pharma Personalization 
(Product) 
• Holistic Integrated Healthcare and Treatment 
(Patient Service) 
• Made to Order 
• Improved Formulation and Platforms 
• Future Therapies and Unmet Needs Solutions 
• Drug Delivery 
• Smart Packaging 
• Data and Customer Understanding 
 
 
 
Discussion/Conclusions 
 
On-going new technology development in the area of ‘Continuous Manufacturing’ (CM) 
has enabled potential for significant step changes within the Pharmaceutical sector e.g. 
shifting from traditional ‘batch’ to ‘continuous’ processing has implications for (a) 
product variety, consistency and functionality (b) energy and resource efficiency (c) 
inventory and customization options and (d) overall industry structure. This specific 
research paper looks to explore and address the operations and supply chain management 
challenges associated with CM through industrial landscape mapping (integrating value 
chain analysis with supply network configuration mapping) that is applicable to a broader 
industrial systems context. The pharmaceutical sector was mapped to provide the basis 
for (a) exploring alternative product-process supply network options and value chain 
implications of a shift to CM and (b) cross-sector analysis involving six previous case 
studies (i.e. six industrial systems that have exhibited different types of disruptive 
innovation). Initial observations involving exemplars from non-Pharma sectors (who 
have reconfigured manufacturing operations to support more dynamic supply) include the 
following: 
 
• Blurring of industry boundaries in almost all cases with ‘connections’ beyond the 
traditional ‘sector’ boundary  
• Platform technologies that support multiple product categories ‘disconnected’ 
from end-user markets requiring institutional support   
• New SN actors providing ‘network integration’ and supply/demand balancing 
capabilities to actively support major supply and demand-side uncertainties  
• ‘Open’ but selective nature of supply networks with models observed that 
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demonstrate open-upstream models (biotechnology), open-downstream models 
(service, last mile), as well as single-product category clusters (maritime) with 
uncertainty/asset pooling coping methodologies selectively deployed to manage 
both technology and market uncertainty 
• Co-existence of ‘product generations’ with particular evolution paths for SNs that 
use distinctly different new assets and diversifying where sunk costs can frustrate 
or significantly constrain development, and  
• Fabless models that draw resources from the wider industrial system 
 
These studies will look to inform development of an emerging analysis framework for 
Pharma (currently at the conceptual level) to enable end-to-end supply chain assessment 
and support overall impact analysis in making the business case for CM. 
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